Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The INNs and outs of antibody nonproprietary names.

Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J, Baker MP.

MAbs. 2016;8(1):1-9. doi: 10.1080/19420862.2015.1114320.

2.

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.

Leung KM, Batey S, Rowlands R, Isaac SJ, Jones P, Drewett V, Carvalho J, Gaspar M, Weller S, Medcalf M, Wydro MM, Pegram R, Mudde GC, Bauer A, Moulder K, Woisetschläger M, Tuna M, Haurum JS, Sun H.

Mol Ther. 2015 Nov;23(11):1722-1733. doi: 10.1038/mt.2015.127. Epub 2015 Aug 3. Erratum in: Mol Ther. 2015 Nov;23(11):1794.

3.

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor.

Koefoed K, Steinaa L, Søderberg JN, Kjær I, Jacobsen HJ, Meijer PJ, Haurum JS, Jensen A, Kragh M, Andersen PS, Pedersen MW.

MAbs. 2011 Nov-Dec;3(6):584-95. doi: 10.4161/mabs.3.6.17955. Epub 2011 Nov 1.

4.

Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans.

Poulsen TR, Jensen A, Haurum JS, Andersen PS.

J Immunol. 2011 Oct 15;187(8):4229-35. doi: 10.4049/jimmunol.1000928. Epub 2011 Sep 19.

5.

Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.

Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M.

Cancer Res. 2010 Jan 15;70(2):588-97. doi: 10.1158/0008-5472.CAN-09-1417. Epub 2010 Jan 12.

6.

Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.

Klitgaard JL, Coljee VW, Andersen PS, Rasmussen LK, Nielsen LS, Haurum JS, Bregenholt S.

J Immunol. 2006 Sep 15;177(6):3782-90.

7.

Recombinant polyclonal antibodies: the next generation of antibody therapeutics?

Haurum JS.

Drug Discov Today. 2006 Jul;11(13-14):655-60. Review.

PMID:
16793535
8.

Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.

Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS.

Curr Pharm Des. 2006;12(16):2007-15. Review.

PMID:
16787244
9.

Allergen-specific polyclonal antibodies reduce allergic disease in a mouse model of allergic asthma.

Moerch U, Haahr Hansen M, Vest Hansen NJ, Rasmussen LK, Oleksiewicz MB, Frandsen TP, Haurum JS, Bregenholt S.

Int Arch Allergy Immunol. 2006;140(3):261-9. Epub 2006 May 11.

PMID:
16699287
10.

Production of target-specific recombinant human polyclonal antibodies in mammalian cells.

Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, Sharon J, Yang CY, Bregenholt S, Nielsen LS, Haurum JS, Tolstrup AB.

Biotechnol Bioeng. 2006 Jun 5;94(2):396-405.

PMID:
16596663
11.

Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen.

Andersen PS, Haahr-Hansen M, Coljee VW, Hinnerfeldt FR, Varming K, Bregenholt S, Haurum JS.

Mol Immunol. 2007 Jan;44(4):412-22. Epub 2006 Apr 3.

PMID:
16581131
12.

Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing.

Meijer PJ, Andersen PS, Haahr Hansen M, Steinaa L, Jensen A, Lantto J, Oleksiewicz MB, Tengbjerg K, Poulsen TR, Coljee VW, Bregenholt S, Haurum JS, Nielsen LS.

J Mol Biol. 2006 May 5;358(3):764-72. Epub 2006 Mar 2.

PMID:
16563430
13.

Antibody engineering--IBC's 15th Annual International Conference. 30 November-3 December 2004, San Diego, CA, USA.

Haurum JS.

IDrugs. 2005 Feb;8(2):91-3. No abstract available. Erratum in: IDrugs. 2005 Mar;8(3):275.

PMID:
15696403
14.

MHC-restricted T cell responses against posttranslationally modified peptide antigens.

Kastrup IB, Andersen MH, Elliott T, Haurum JS.

Adv Immunol. 2001;78:267-89. Review. No abstract available.

PMID:
11432206
15.

Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo.

Kastrup IB, Stevanovic S, Arsequell G, Valencia G, Zeuthen J, Rammensee HG, Elliott T, Haurum JS.

Tissue Antigens. 2000 Aug;56(2):129-35.

PMID:
11019912
16.

Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules.

Andersen MH, Tan L, Søndergaard I, Zeuthen J, Elliott T, Haurum JS.

Tissue Antigens. 2000 Jun;55(6):519-31.

PMID:
10902608
17.

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.

Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS.

Leukemia. 2000 Mar;14(3):419-26.

PMID:
10720136
18.

Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.

Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, Neefjes J, Zeuthen J, Elliott T, Haurum JS.

J Immunol. 1999 Oct 1;163(7):3812-8. Erratum in: J Immunol 2000 May 15;164(10):5531.

19.

An assay for peptide binding to HLA-Cw*0102.

Andersen MH, Søndergaard I, Zeuthen J, Elliott T, Haurum JS.

Tissue Antigens. 1999 Aug;54(2):185-90.

PMID:
10488746
20.

Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo.

Haurum JS, Høier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T.

J Exp Med. 1999 Jul 5;190(1):145-50.

21.

Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity.

Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, Springer S, Townsend A, Pao YL, Wormald M, Dwek RA, Jones EY, Elliott T.

Immunity. 1999 Jan;10(1):63-74.

22.

Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.

Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF.

J Immunol. 1997 Dec 1;159(11):5211-8.

PMID:
9548459
23.

An improved assembly assay for peptide binding to HLA-B*2705 and H-2K(k) class I MHC molecules.

Tan L, Andersen MH, Elliott T, Haurum JS.

J Immunol Methods. 1997 Nov 10;209(1):25-36.

PMID:
9448031
24.

MUC1 peptide epitopes associated with five different H-2 class I molecules.

Apostolopoulos V, Haurum JS, McKenzie IF.

Eur J Immunol. 1997 Oct;27(10):2579-87.

PMID:
9368613
25.

Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition.

Haurum JS, Tan L, Arsequell G, Frodsham P, Lellouch AC, Moss PA, Dwek RA, McMichael AJ, Elliott T.

Eur J Immunol. 1995 Dec;25(12):3270-6.

PMID:
8566011
26.

[The cell mediated immune response].

Haurum JS.

Ugeskr Laeger. 1995 Jul 3;157(27):3887-93. Review. Danish.

PMID:
7645062
27.
28.

Binding of human collectins (SP-A and MBP) to influenza virus.

Malhotra R, Haurum JS, Thiel S, Sim RB.

Biochem J. 1994 Dec 1;304 ( Pt 2):455-61.

29.

Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes.

Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, Elliott T.

J Exp Med. 1994 Aug 1;180(2):739-44.

30.

Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins.

Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC.

AIDS. 1993 Oct;7(10):1307-13.

PMID:
8267903
31.

Supplemental Content

Loading ...
Support Center